| INTRODUC TI ON
of haemophilia B prevalence vary from 1.7 4 to 8.07 5 cases per 100 000 males. Approximately 30% of patients with haemophilia A have no family history of symptomatic disease. 6 Replacement therapy comprising plasma-derived or recombinant factor concentrates is the mainstay of haemophilia A and B treatment. Replacement therapy can be administered prophylactically on a regular basis and/or on-demand to treat bleeding episodes. 7 Haemophilia diagnosis and disease severity classification are determined based on FVIII and FIX activity assay results. Factor activity assays are also used for potency labelling and postinfusion monitoring of factor replacement products (both plasma-derived and recombinant), as well as for testing for FVIII/FIX inhibitors (ie alloantibodies against the missing or defective factor). [8] [9] [10] Accurate factor activity assays are, therefore, crucial for appropriate diagnosis and therapeutic intervention in patients with haemophilia.
Factor activity assays include one-stage assays (OSAs), based on activated partial thromboplastin time (APTT), and two-stage chromogenic substrate assays (CSAs), which comprise a FXa-based enzymatic chromophore substrate reaction. OSAs are the most widely used in diagnostic laboratories. In a global survey conducted across 7 countries, 90% and 88% of laboratory scientists used OSAs to diagnose haemophilia A and B, respectively. 4 In a European survey conducted in 2013
by the External quality Control of diagnostic Assays and Tests (ECAT)
Foundation, 90% of laboratory scientists used OSAs to diagnose haemophilia A, compared with only 6% who used CSAs. 11 Notably, many different OSA reagents, as well as methodologies, were used across these laboratories. While most clinical laboratories do not offer CSAs, there are advantages to offering both methodologies to measure FVIII and FIX activity, especially in clinical laboratories that are involved in the care of patients with haemophilia A and/or B.
This article provides an overview of the methodology, use, implementation and performance of FVIII and FIX OSAs and CSAs in clinical laboratories, while it also offers specific recommendations, with the aim of increasing awareness and establishing best practices by both laboratory scientists and clinicians. Limitations and advantages of each type of assay are highlighted to facilitate an understanding of current practice, argue in favour of the implementation of both assay types, and improve communication not only between the laboratory scientists and clinicians but also among factor replacement product and instrument/reagent manufacturers.
| PRIN CIPLEANDME THODOLOGYOF ONE-S TAG EANDCHROMOG ENI CF VIII ANDFIXAC TIVIT YA SSAYS

| APTT-basedOSAs
APTT-based OSAs measure the ability of a test plasma sample to correct a prolonged coagulation time (ie shorten the APTT) of FVIIIor FIX-deficient plasma (Table 1) . 8, 12, 13 A general description of APTT-based OSA methodology is provided below, although it should be noted that there is a plethora of different reagents and assay conditions, as well as several instrument types available, all of which contribute to variability in the results obtained. 
| CSAs
FVIII and FIX CSAs are two-stage assays (Table 1) . 19 First, test plasma is added to a mixture containing the appropriate cofactors, FX, thrombin or prothrombin (optional), calcium and phospholipid, and this mixture is incubated for 2-10 minutes (Figure 3 ). This reaction leads to the production of activated FX (FXa). When the reaction is stopped, the amount of FXa generated is proportional to the amount of functional factor FVIII or FIX in the sample. The assay uses an FXa-specific peptide nitroanilide substrate, which is cleaved by FXa to produce coloured p-nitroaniline that can be measured with a spectrophotometer. The colour intensity is proportional to the amount of functional factor in the sample and is established by reading off a standard curve. 19 In contrast to OSAs, CSAs tend to be performed in duplicate at one dilution and do not require the addition of factor-deficient plasma.
| COMPARISONOFONE-S TAG EAND CHROMOG ENI CF VIIIANDFIXAC TIVIT Y A SSAYS
| Useandapprovalstatus
OSAs are the most widely used factor activity assays in diagnostic laboratories (Table 2) . 4 They are perceived as less technically F I G U R E 1 One-stage APTT-based factor activity assay principle. Serial dilutions of a citrated test plasma sample, mixed with equivalent volumes of factor (F) VIII-or FIX-deficient plasma, are incubated for 3-5 min at 37°C together with phospholipids (derived from soybean, rabbit or bovine brain, human placenta, of synthetic origin or a combination of materials) and a contact activator (silica, kaolin, celite, ellagic acid, dextran sulfate or sulfatides). Clotting is initiated by the addition of calcium. The time required for clot formation (measured as activated partial thromboplastin time [APTT] ) is proportional to the extent of factor deficiency in the test sample complex than CSAs, the latter considered more complicated and slower due to a lack of familiarity by laboratory scientists. 10, 20 OSAs are also considered easier to automate. 19 Furthermore, the overriding perception is that OSAs are less expensive than CSAs. 10 It should be noted, however, that significant cost reductions can be achieved with appropriate CSA protocols and reagent handling, for example, by performing batch analyses or by storing reagents frozen in aliquots, if acceptable according to regulatory requirements. 10, 20 The predominance of OSAs is also supported by the United States (US) Food and Drug Administration's (FDA) recommendation that these are used for potency labelling of both FVIII and FIX products. 10 Furthermore, in Europe, the European Pharmacopoeia (Ph Eur) also recommends OSAs for FIX potency assignments, although
CSAs are recommended for FVIII potency assignments. 
| Assayperformance:Reagentvariability,assay sensitivityandavailableprotocols
Despite the widespread use of OSAs in laboratories worldwide, there are several factors that can limit their performance (Table 2 ).
For example, there are many different commercial APTT reagents available, 12 and some reagents can be manufactured to be more sensitive to factor deficiencies and/or more sensitive to the presence of lupus anticoagulants. In addition, there are a number of factordeficient plasmas that can be used, either congenital in nature or immunodepleted of specific factors. Moreover, there is no international standardization of APTT-based OSA methodology, which, combined with the wide range of both APTT reagents and factordeficient plasmas available, has contributed to discrepancies among factor activity results between laboratories. 4 F I G U R E 2 Examples of parallel and nonparallel one-stage FVIII activity assay results. Results from an activated partial prothrombin time (APPT)-based one-stage activity assay used to measure factor VIII (FVIII) are shown. The 3 points on the parallelism curves were derived from 1:10, 1:20 and 1:40 dilutions of (A) normal and (B) patient samples. The sample used in (B) was from a patient with a strong lupus anticoagulant that shows nonspecific inhibition of the clotting reaction. In the case of parallelism, as shown in (A), typically, the average of the results for all 3 dilutions is reported as "% factor activity." In the case of nonparallelism, as shown in (B), it is usually the highest result that is reported or, alternatively, additional dilutions, such as 1:80 ) and phospholipid (PL), and this mixture is incubated for 2-10 min. In this reaction, activated FVIII (FVIIIa) (A) or activated FXI (FXIa) (B) is generated and this leads to the production of activated FX (FXa). When the reaction is stopped, the amount of FXa that is generated is proportional to the amount of functional FVIII or FIX in the sample. The assay uses an FXa-specific peptide nitroanilide substrate, which is cleaved by FXa to produce coloured p-nitroaniline that can be measured with a spectrophotometer by absorbance at 405 nm. The colour intensity is considered proportional to the amount of functional factor in the sample TA B L E 2 Advantages and disadvantages of one-stage clotting and chromogenic substrate assays for measuring factor VIII and factor IX activity in the deficient plasma. Factor-deficient plasma that is immunodepleted may also contain small amounts of activated factor V, which could lead to falsely elevated factor activity results (by shortening the clotting time). Moreover, immunodepleted plasma may also have low VWF levels compared with congenital-deficient plasma, resulting in apparent decreased factor activity levels. 31 It is particularly important to test the factor level of factor-deficient plasma upon lot change. In addition, normal concentrations of VWF in FVIII-deficient plasma have been shown to improve accuracy in FVIII OSAs used to establish the presence of FVIII inhibitors. 14 In addition, contamination of factor-deficient plasma with antibodies co-eluted from the column used during the immunodepletion process is possible. 32 Factor-deficient plasma from patients with a severe congenital factor deficiency (ie <1 IU/dL [1% of normal]) on the other hand may also contain inhibitors and should, therefore, be established as inhibitor-free prior to being used in OSAs. 12 It is also recommended that patients remain untreated for a sufficient period of time (usually 2 weeks) prior to harvesting the plasma in order to ensure zero factor activity. Overall, for OSAs, it is advisable to use normal plasma that has been rendered factor deficient through immunodepletion with a monoclonal antibody rather than using haemophilic plasma. 17 Haemophiliac plasma is more costly, and there is a higher risk that it may contain an inhibitor or replacement product. If the use of haemophiliac plasma cannot be avoided due to cost constraints (eg in developing countries), it is imperative that this is rigorously tested to exclude the presence of inhibitors. 40 Moreover, CSAs with human reagents can be used to monitor emicizumab activity in vitro. 41 Emicizumab levels cannot be measured accurately using OSAs, as clot-based activity assays lead to a gross overestimation of drug levels. 42 For both OSAs and CSAs, testing against the WHO IS for FIX concentrates is required for potency labelling of new FIX products.
An important limitation of CSAs is that most assay manufac
However, the potency of the WHO FIX IS itself is often determined primarily by using results from OSAs. 15, 43 In addition, CSAs are currently not validated for potency labelling of new FIX products, and therefore, it is recommended that the relevance of FIX potencies determined using this method is assessed for each individual FIX product. 44 In cases in which OSAs and CSAs provide invalid (ie nonparallel/nonlinear) results against the WHO IS in potency assignment of new factor replacement products, use of a product-specific standard can improve assay accuracy. 44 This approach is associated with both advantages and disadvantages. 10 Using a productspecific standard allows standardization of results between assays and is also consistent with the so-called like-versus-like principle set out by the Sub-committee of the Scientific and Standardization
Committee (SSC) of the International Society on Thrombosis and
Haemostasis (ISTH), whereby the type of test sample (eg plasma or concentrate), the type of factor (native or recombinant) and the citrate concentration of the test sample should be of similar composition as the standard. 45 In addition, a product-specific standard may provide greater reliability in postinfusion clinical monitoring through more accurate determination of factor activity levels, as shown in the case of ReFacto AF ® -treated patients. 46 Conversely, using a product-specific standard can be a time-and resourceconsuming process, as each product standard must be validated for each assay. With new recombinant products becoming available, an ever-increasing number of standards will be required. Furthermore, the use of a product-specific standard renders each assay an LDT, thus requiring a greater degree of validation compared with an FDA-approved assay. A final, but equally important, point is that ensuring the appropriate assay methodology and/or reagent is used with each product-specific standard, depending on the clinical profile and type of treatment, requires high-level communication between laboratories and treatment centres, which may be difficult to establish and ensure in some cases. of normal factor activity. 12, 18 Although CSAs may be more sensitive than some OSAs in the detection of extremely low FVIII activity levels (eg in patients with severe haemophilia A), there is variability depending on the manufacturer-defined LLOQ of the CSA used. 45 It should be noted that when high or low calibration curves are used (in either OSAs or CSAs), each curve should have 2 controls (normal and abnormal/pathological). 12 It is not advisable to extrapolate results that fall outside the range of the standard curve. 18 In OSA systems that utilize high and low calibration curves, more accurate results can be obtained when the material for the low curve as well as the patient plasma are diluted into factor-deficient plasma rather than buffer. 48 In cases in which the calibration material for the low curve is diluted in buffer, the matrix of the calibration medium will be different than that of the test samples, resulting in prolonged clotting times for the calibration material for a given factor activity and, consequently, factor clotting activity results in the patient sample that are falsely elevated. It is recommended that factor activity assays are calibrated at least every 6 months; however, some laboratories may choose to calibrate more frequently. 59 In the authors' experience, a calibration curve stored for several months can also be used with the FVIII CSA.
| Measurementoflowfactorlevels
| Diagnosisandclassificationof discrepantnonseverehaemophilia
Several guidelines recommend that assay calibration and patient sample analysis be performed in parallel. 18, 56 However, a global survey of laboratory scientists found that 54% of participants ran a calibration curve with every FVIII assay, with the remaining 46% using a stored curve, generally recalibrated weekly or monthly. The calibration process was reported to take an average of 28 minutes and a commercial calibrator was used by 85% of participants. 4 It is crucial that a calibration curve is generated whenever there is a change in reagent or reagent lot, if quality control materials reflect an unusual trend or shift or are outside of the laboratory's acceptable limits, and if other methods of assessing and correcting unacceptable control values fail to identify and correct the problem after major maintenance or service based on the manufacturers' recommendations.
14,16
| CON CLUS IONS
Fostering good communication between product manufacturers, laboratory scientists and clinicians is key in ensuring that the appropriate factor activity assays and reagents are used. It is important that clinicians are aware of the advantages and limitations of factor activity assays for the diagnosis and disease severity classification of haemophilia and for monitoring of postinfusion samples. It is equally important that laboratory scientists are able to make suggestions on the choice of available methods. In addition, information on monitoring of different products must not only be available in the published literature but should also be provided by product manufacturers.
It is crucial to ensure that nonsevere haemophilia A is not "missed"
or misclassified due to discrepancies in results between OSAs and
CSAs. There are sufficient data to recommend that CSAs should be performed in combination with OSAs for patients with nonsevere haemophilia A.
New modified recombinant factor replacement products entering the market may benefit from recommendations for appropriate assays in the package inserts. With new treatment options for haemophilia, factor activity assay awareness and methodology will need to keep pace and adjustments made in a timely fashion.
Given that authoritative bodies are now recommending the incorporation of CSAs "once approved," it is important that laboratories adapt accordingly to be able to offer this service and take part in regular proficiency testing. Alternatively, some testing may need to be outsourced to laboratories that can provide the appropriate assays. These specialized laboratories could also act as centres of excellence, providing support and advice.
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